A consensus statement regarding the utilization of BMP in spine surgery
Authors:
- John KoernerJKJohn Koerner
- Kris RadcliffKRKris Radcliff
- 20 June 2014
- journal article
- Published by Springer Nature in Current Reviews in Musculoskeletal Medicine
- Vol. 7 (3) , 208-219
Abstract
Recombinant human bone morphogenetic protein - 2 (rh-BMP-2) was first approved by the United States Food and Drug Administration (FDA) in 2002 for use in anterior lumbar interbody fusions. Since that time, it has been estimated that “off label” use accounts for 85 % of applications. Original, industry sponsored studies demonstrated superior fusion rates with decreased incidence of complications when compared with traditional iliac crest bone graft. These studies have been criticized for potential bias and newer research has detailed potential complications as well as alternative applications. Potential off label uses of rhBMP-2 include: anterior lumbar fusions, single level posterior lumbar fusions, multiple level posterior lumbar fusions, posterior cervical fusions, long deformity fusions, in the presence of vertebral osteomyelitis, and in patients with history of malignancy. A review of the literature related to rhBMP-2 was conducted to evaluate its use for the above-mentioned applications with a special focus on fusion rates, observed complications, and clinical or radiographic outcomes.Keywords
This publication has 61 references indexed in Scilit:
- Recombinant Human Bone Morphogenetic Protein-2 (BMP) Use in Adult Spinal Deformity (ASD) Does Not Increase Major, Infectious or Neurological Complications and May Decrease Return to Surgery at One Year: A Prospective, Multicenter AnalysisThe Spine Journal, 2013
- Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderlyJournal of Orthopaedic Surgery and Research, 2013
- BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumorsBMC Cancer, 2012
- Mesenchymal stem cells with rhBMP-2 inhibits the growth of canine osteosarcoma cellsBMC Veterinary Research, 2012
- Use of Bone Morphogenetic Proteins in Spinal Fusion Surgery for Older Adults With Lumbar StenosisSpine, 2012
- Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell linesThe Laryngoscope, 2011
- A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learnedThe Spine Journal, 2011
- The efficacy of rhBMP-2 versus autograft for posterolateral lumbar spine fusion in elderly patientsEuropean Spine Journal, 2009
- Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non–instrument-assisted lumbar decompression and fusionSurgical Neurology, 2008
- Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin β1 into lipid raftsExperimental Cell Research, 2006